Pharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher methotrexate bioavailability in psoriasis plaques than in non-lesional skin

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 9, 2016, Pages 1537-1543

  Quist, S R ^a   Quist, J ^a   Birkenmaier, J ^b   Stauch, T ^b   Gollnick, H P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Laboratory Volkmann   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; AREA UNDER THE CURVE; AREA UNDER THE MOMENT CURVE; ARTICLE; CATHETER; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DIALYSIS MEMBRANE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; EX VIVO STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERSTITIAL FLUID; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEDICATION COMPLIANCE; MICRODIALYSIS; MICRODIALYSIS CATHETER; MIDDLE AGED; PATIENT COMPLIANCE; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SERUM; SYRINGE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84983071342     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13656     Document Type: Article

References (31)

1. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007; 20(216–22): 8.
2. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094–1099.
3. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73–81.
4. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007; 46: 1520–1524.
5. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 2009; 91: 51–58.
6. Stagni G, Shukla C. Pharmacokinetics of methotrexate in rabbit skin and plasma after iv-bolus and iontophoretic administrations. J Control Release 2003; 93: 283–292.
7. Kampf G, Wigger-Alberti W, Wilhelm KP. Do atopics tolerate alcohol-based hand rubs? A prospective, controlled, randomized double-blind clinical trial. Acta Derm Venereol 2006; 86: 140–143.
8. Agner T. Susceptibility of atopic dermatitis patients to irritant dermatitis caused by sodium lauryl sulphate. Acta Derm Venereol 1991; 71: 296–300.
9. Qian CY, Yuan C, Tan YM et al. Comparing performance of Chromameter(R), Mexameter(R) and full-field laser perfusion imaging for measurement of ultraviolet B light-induced erythema. Clin Exp Dermatol 2015; 40: 438–440.
10. Dornelles S, Goldim J, Cestari T. Determination of the minimal erythema dose and colorimetric measurements as indicators of skin sensitivity to UV-B radiation. Photochem Photobiol 2004; 79: 540–544.
11. Muller M, Brunner M, Schmid R et al. Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res 1998; 58: 2982–2985.
12. Dukic S, Kaltenbach ML, Gourdier B, Marty H, Vistelle R. Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. Pharm Res 1998; 15: 133–138.
13. Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008; 33: 551–554.
14. Ekstrom PO, Andersen A, Warren DJ, Giercksky KE, Slordal L. Determination of extracellular methotrexate tissue levels by microdialysis in a rat model. Cancer Chemother Pharmacol 1996; 37: 394–400.
15. Dukic S, Heurtaux T, Kaltenbach ML et al. Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. Pharm Res 1999; 16: 1219–1225.
16. Dukic SF, Kaltenbach ML, Heurtaux T, Hoizey G, Lallemand A, Vistelle R. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. J Neurooncol 2004; 67: 131–138.
17. Maia MB, Saivin S, Chatelut E, Malmary MF, Houin G. In vitro and in vivo protein binding of methotrexate assessed by microdialysis. Int J Clin Pharmacol Ther 1996; 34: 335–341.
18. Wong TW, Zhao YL, Sen A, Hui SW. Pilot study of topical delivery of methotrexate by electroporation. Br J Dermatol 2005; 152: 524–530.
19. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001; 215: 57–65.
20. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm 2001; 212: 101–107.
21. Matsuyama K, Nakashima M, Nakaboh Y, Ichikawa M, Yano T, Satoh S. Application of in vivo microdialysis to transdermal absorption of methotrexate in rats. Pharm Res 1994; 11: 684–686.
22. Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol 2008; 60: 27–33.
23. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, Gallo JM. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2007; 43: 1789–1795.
24. Chladek J, Simkova M, Vaneckova J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347–355.
25. Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008; 22: 19–24.
26. Swierkot J, Slezak R. The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1). Postepy Hig Med Dosw (Online) 2011; 65: 195–206.
27. Plaza-Plaza JC, Aguilera M, Canadas-Garre M et al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS 2012; 16: 589–595.
28. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299–3308.
29. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 2014; 32: 563–571.
30. Muller-Ladner U, Rockwitz K, Brandt-Jurgens J et al. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J 2010; 4: 15–22.
31. Hider SL, Morgan C, Bell E, Bruce IN. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA? Ann Rheum Dis 2003; 62: 591; author reply 591–592.